GlassScriptPhysician profile
David Mark Wilson
NPI 1326468901
$3,276.48
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $864 · 2020: $452 · 2021: $1,742 · 2022: $218.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $941.85 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $668.52 | 2019-2021 | |
| Novo Nordisk INC | $258.95 | 2019-2022 | |
| Abbvie INC. | $228.68 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.32 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $124.55 | 2019-2021 | |
| Lilly USA, LLC | $121.39 | 2019-2021 | |
| Genentech USA, INC. | $107.07 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $106.16 | 2020-2021 | |
| Amgen INC. | $82.25 | 2019 | |
| Merck Sharp & Dohme LLC | $52.25 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.35 | 2021-2022 | |
| Eisai INC. | $46.52 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $44.53 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.05 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $38.63 | 2019 | |
| Astellas Pharma US INC | $31.54 | 2019 | |
| Glaxosmithkline, LLC. | $25.55 | 2020-2021 | |
| Becton, Dickinson and Company | $25.08 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.30 | 2021 | |
| Amneal Pharmaceuticals LLC | $17.84 | 2021 | |
| Sanofi Pasteur INC. | $16.13 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.86 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $13.74 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.34 | 2021 | |
| Ironwood Pharmaceuticals, INC | $11.03 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.